Recent advances towards the discovery of ORL-1 receptor agonists and antagonists

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 4, 2005, Pages 357-388

  Bignan, Gilles C ^a   Connolly, Peter J ^a   Middleton, Steven A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anxiety; Aryl piperidines; Benzimidazolyl piperidines; Cognition; Cough; Diuresis; Learning; Memory; Morphinans; N OFQ peptide (NOP); Nociceptin; Opioid receptor like (ORL); ORL 1; Orphanin FQ (OFQ); Pain; Quinazolines; Quinolines; Spiro piperidines; Stress

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1,3,8 TRIAZASPIRODECANONE DERIVATIVE; 8 (2,3,3A,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL) 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DECAN 4 ONE; [8 (1 NAPHTHYLMETHYL) 4 OXO 1 PHENYL 1,3,8 TRIAZASPIRO[4.5]DEC 3 YL]ACETIC ACID METHYL ESTER; AMINO ACID; BUPRENORPHINE; DELTA OPIATE RECEPTOR; FUROSEMIDE; J 112444; KAPPA OPIATE RECEPTOR; LIGAND; LOFENTANIL; MORPHINE; MU OPIATE RECEPTOR; N (4 AMINO 2 METHYL 6 QUINOLINYL) 2 (4 ETHYLPHENOXYMETHYL)BENZAMIDE; NALFURAFINE; NALOXONE BENZOYLHYDRAZONE; NNC 63 0780; NOCICEPTIN; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; OPIATE AGONIST; OPIATE ANTAGONIST; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RO 65 6570; UFP 101; UNCLASSIFIED DRUG; ZP 120;

ACUTE HEART FAILURE; ALCOHOLISM; ALLODYNIA; ANOREXIA; ANXIETY DISORDER; ASTHMA; BINDING AFFINITY; CACHEXIA; CLINICAL TRIAL; COGNITION; COUGHING; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DESIGN; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL MOTILITY; HUMAN; HYPERTENSION; MIGRAINE; MOTOR DYSFUNCTION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPIATE ADDICTION; OVERACTIVE BLADDER; PAIN; PARKINSONISM; PATENT; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SEQUENCE HOMOLOGY; SIDE EFFECT; STRESS; STRUCTURE ACTIVITY RELATION; SUBSTANCE ABUSE; URINE INCONTINENCE; WATER RETENTION;

EID: 18144431042     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.4.357     Document Type: Review

References (143)

1. COX BM, CHAVKIN C, CHRISTIE MJ et al.: Opioid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. Girdlestone D (Ed.), IUPHAR Media Ltd, London (2000):321-333.
2. MEUNIER JC, MOLLEREAU C, TOLL L et al.: Isolation and structure of the endogenous agonist of opioid receptor-like ORL-1 receptor. Nature (1995) 377(6549):532-535.
3. REINSCHEID RK, NOTHACKER HP, BOURSON A et al.: Orphanin FQ: A neuropeptide that activates an opioid like G-protein-coupled receptor. Science (1995) 270(5237):792-794.
4. MOLLEREAU C, PARMENTIER M, MAILLEUX P et al.: ORL-1, a novel member of the opioid receptor family - cloning, functional expression and localization. FEBS Lett. (1994) 341(1):33-38.
5. HRUBY VJ, GEHRIG CA: Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. (1989) 9(3):343-401.
6. PATERSON SJ, KOSTERLITZ HW, VAVREK RJ et al.: Effects of D-amino acid substitution in dynorphin A (1-9) on binding at the mu-, delta- and kappa-sites. Neuropeptides (1984) 5(1-3):177-180.
7. SHIMOHIGASHI Y: Design principles: enkephalins with predictable mu/delta receptor specificity. Natl. Inst. Drug Abuse Res. Monogr. Ser. (1986) 69:65-100
8. REINSCHEID RK, ARDATI A, MONSMA FJ JR et al.: Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. (1996) 271(24):14163-14168.
9. BUTOUR J-L, MOISAND C, MAZARGUIL H et al.: Recognition and activation of the opioid receptor-like ORL-1 receptor by nociceptin, nociceptin analogs and opioids. Eur. J. Pharmacol. (1997) 321(1):97-103.
10. GUERRINI R, CALO G, RIZZI A et al.: Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. (1997) 40(12):1789-1793.
11. REINSCHEID RK, HIGELIN J, HENNINGSEN RA et al.: Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J. Biol. Chem. (1998) 273(3):1490-1495.
12. SHIMOHOGASHI Y, HATANO R, FUJITA T et al.: Sensitivity of opioid receptor-like receptor ORL-1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J. Biol. Chem. (1996) 271(31):23642-23645.
13. 1-9 are ligands for the κ-subtype of opiate receptor. Nature (1982) 299(5878):79-81.
14. SEKI T, MINAMI M, KIMURA C et al.: Bremazocine recognizes the difference in four amino acid residues to discriminate between a nociceptin/orphanin FQ receptor and opioid receptors. Jpn. J. Pharmacol. (1998) 77(4):301-306.
15. LAPALU S, MOISAND C, BUTOUR J-L et al.: Different domains of the ORL-1 and κ-opioid receptors are involved in recognition of nociceptin and dynorphin A. FEBS Lett. (1998) 427(2):296-300.
16. MENG F, UDE Y, HOVERSTEN MT et al.: Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. Mol. Pharmacol. (1998) 53(4):772-777.
17. MENG F, TAYLOR LP, HOVERSTEN MT et al.: Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J. Biol. Chem. (1996) 271(50):32016-32020.
18. PAN YX, XU J, RYAN-MORO J et al.: Dissociation of affinity and efficacy in KOR-3 chimeras. FEBS Lett. (1996) 395(2-3):207-210.
19. MOLLEREAU C, MOISAND C, BUTOUR J-L et al.: Replacement of Gln280 by His in TM6 of the human ORL-1 receptor increases affinity but reduces intrinsic activity of opioids. FEBS Lett. (1996) 395(1):17-21.
20. CONNOR M, VAUGHAN, CW, CHIENG B et al.: Nociceptin receptor coupling to a potassium conductance in rat locus ceruleus neurons in vitro. Br. J. Pharmacol. (1996) 119(8):1614-1618.
21. VAUGHAN C, CHRISTIE MJ: Increase by the ORL-1 receptor (opioid receptor-like-1) ligand, nociceptin, of inwardly rectifying K conductance in dorsal raphe nucleus neurons. Br. J. Pharmacol. (1996) 117(8):1609-1611.
22. MATTHES H, SEWARD EP, KIEFFER B et al.: Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes. Mol. Pharmacol. (1996) 50(3):447-450.
23. VAUGHAN C, INGRAM SL, CHRISTIE MJ et al.: Actions of the ORL-1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J. Neurosci. (1997):17(3):996-1003.
24. + channel in Xenopus oocytes. Br. J. Pharmacol. (1997) 120(6):986-987.
25. + (GIRK) channel. Mol. Brain Res. (1997) 45(1):117-126.
26. 2+ in the SH-SY5Y human neuroblastoma cell line. Br. J. Pharmacol. (1996) 118(2):205-207.
27. KNOFLACH F, REINSCHEID RK, CIVELLI O et al.: Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J. Neurosci. (1997) 16(21):6657-6664.
28. 2+ channel currents of acutely dissociated rat periaqueductal gray neurons. J. Physiol. (1998) 509(1):47-58.
29. FUKUDA K, SHODA T, MORIKAWA H et al.: Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett. (1997) 412(2):290-294.
30. i-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization. J. Neurochemistry (1998) 71(3):1024-1033.
31. LOU L-G, ZHANG Z, MA L et al.: Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor. J. Neurochem. (1998) 70(3):1316-1322.
32. + evoked glutamate release from rat cerebrocortical slices. Br. J. Pharmacol. (1996) 119(6):1081-1083.
33. LIEBEL JT, SWANDULLA D, ZEILHOFER HU: Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurons of the neonatal rat spinal cord. Br. J. Pharmacol. (1997) 121(3):425-432.
34. LAI CC, WU SY, DUN SL et al.: Nociceptin-like immunoreactivity in the rat dorsal horn and inhibition of substantia gelatinosa neurons. Neuroscience (1997) 81(4):887-891.
35. PATEL HJ, GIEMBYCZ MA, SPICUZZA L et al.: Naloxone-insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea pig trachea by the novel opioid, nociceptin. Br. J. Pharmacol. (1997) 120(5):735-736.
36. NEAL MJ, CUNNINGHAM JR, PATERSON SJ et al.: Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurons. Br. J. Pharmacol. (1997) 120(8):1399-1400.
37. GIULIANI S, MAGGI CA: Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br. J. Pharmacol. (1996) 118(7):1567-1569.
38. FISCHERA, FORSSMANN WG, UNDEM BJ: Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus. J. Pharmacol. Exp. Ther. (1998) 285(2):902-907.
39. SCHLICKER E, WERTHWEIN S, KATHMANN M et al.: Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL-1 Receptors. Naunyn-Schmied. Arch. Pharmacol. (1998) 358(4):418-422.
40. DARLAND T, HEINRICHER MM, GRANDY DK: Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci. (1998) 21(5):215-221.
41. HOUTANI T, NISHI M, TAKESHIMA H et al.: Structure and regional distribution of nociceptin/orphanin FQ precursor. Biochem. Biophys. Res. Comm. (1996) 219(3):714-719.
42. LACHOWICZ JE, SHEN Y, MONSMA FJ JR et al.: Molecular cloning of a novel G-protein-coupled receptor related to the opiate family. J. Neurochem. (1995) 64(1):34-40.
43. MEIS S, PAPE HC: Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J. Neurosci. (1998) 18(20):8133-8144.
44. 3H]nociceptin binding sites in the rat brain. Brain Res. (1997) 880(1,2):11-16.
45. 125I-(14Tyr)-orphanin FQ binding. J. Comp. Neurol. (1999) 412(4):563-605.
46. 125I[Tyr10]Orphanin FQ/Nociceptin(1-11) binding sites in rat brain. J. Comp. Neurol. (2000) 423(2):319-329.
47. PELUSO J, LAFORGE KS, MATTHES HW et al.: Distribution of nociceptin/ orphanin FQ receptor transcript in human central nervous system and immune cells. J. Neuroimmunol. (1998) 81(1-2):184-192.
48. 125I[Tyr14] nociceptin/ orphanin FQ Binding sites in macaque primate CNS. Neuroscience (2003) 118(2):513-523.
49. RIEDL M, SHUSTER S, VULCHANOVA L et al.: Orphanin FQ/nociceptin-immunoreactive nerve fibers parallel those containing endogenous opioids in rat spinal cord. Neuroreport (1996) 7(8):1369-1372.
50. SCHULZ S, SCHREFF M, NUE D et al.: Nociceptin/orphanin FO and opioid peptides show overlapping distribution but not co-localization in pain-modulatory brain regions. Neuroreport (1996) 7(18):3021-3025.
51. ZEILHOFER HU, CALO G: Nociceptin/orphanin FQ and its receptor-potential targets for pain therapy? J. Pharmacol. Exp. Ther. (2003) 306(2):423-429.
52. MEUNIER J-C: Utilizing functional genomics to identify new pain treatments: the example of nociceptin. Am. J. Pharmacogenomics (2003) 3(2):117-130.
53. NISHI M, HOUTANI T, NODA Y et al.: Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphanin FQ receptor. EMBO J. (1997) 16(8):1858-1864.
54. ROSSI GC, LEVENTHAL L, PASTERNAK GW et al.: Naloxone sensitive orphanin FQ induced analgesia in mice. Eur. J. Pharmacol. (1996) 311(2/3):R7-R8.
55. ROSSI GC, PERLMUTTER M, LEVENTHAL L et al.: Orphanin FQ/nociceptin analgesia in the rat. Brain Res. (1998) 792(2):327-330.
56. MOGIL JS, GRISEL JE, REINSCHEID RK et al.: Orphanin FQ is a functional anti-opioid peptide. Neuroscience (1996) 75(2):333-337.
57. SUAUDEAU C, FLORIN S, MEUNIER J-C et al.: Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanalgesic mechanisms triggered by the stress of an intracerebroventricular injection. Fundam. Clin. Pharmacol. (1998) 12(4):420-425.
58. XU X-J, HAO J-X, WIESENFELD-HALLIN Z: Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport (1996) 7(13):2092-2094.
59. KING MA, ROSSI GC, CHANG AH et al.: Spinal analgesic activity of orphanin FQ/nociceptin and its fragments. Neurosci. Lett. (1997) 223(2):113-116.
60. TIAN JH, XU W, FANG Y et al.: Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Brit. J. Pharmacol. (1997) 120(4):676-680.
61. JHAMANDAS KH, SUTAK M, HENDERSON G et al.: Antinociceptive and morphine modulatory actions of spinal orphanin FQ. Can. J. Physiol. Pharmacol. (1998) 76(3):314-324.
62. HAO J-X, XU IS, WIESENFELD-HALLIN Z et al.: Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain (1998) 76(3):385-393.
63. YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Effects of intrathecally administered nociceptin, an opioid receptor-like-1 (ORL-1) receptor agonist, on the thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci. Lett. (1997) 224(2):107-110.
64. YAMAMOTO T, NOZAKI-TAGUCHI N: Effects of intrathecally administered nociceptin, an opioid receptor-like-1 receptor agonist, and N-methyl-D-aspartate receptor antagonists on the thermal hyperalgesia induced by partial sciatic nerve injury in the rat. Anesthesiology (1997) 87(5):1145-1152.
65. YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Effects of intrathecaly administered nociceptin, an opioid receptor-like-1 (ORL-1) receptor agonist, on the thermal hyperalgesia induced by carageenan injection into the rat paw. Brain Res. (1997) 754(1,2):329-332.
66. YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like-1 receptor agonist, in the rat formalin test. Neuroscience (1997) 81(1):249-254.
67. ERB K, LIEBEL JT, TEGEDER I et al.: Spinally delivered nociceptin/orphanin FQ reduces flinching behavior in the rat formalin test. Neuroreport (1997) 8(8):1967-1970.
68. DAWSON-BASOA M, GINTZLER AR: Nociceptin (orphanin FQ) abolishes gestational and ovarian sex steroid-induced antinociception and induces hyperalgesia. Brain Res. (1997) 750(1,2):48-52.
69. OKUDA-ASHITAKA E, TACHIBANA S, HOUTANI T et al.: Identification and characterization of an endogenous ligand for opioid receptor homolog ROR-C: its involvement in allodynic response to innocuous stimulus. Mol. Brain Res. (1996) 43(1,2):96-104.
70. XU X, GRASS S, HAO J et al.: Nociceptin/orphanin FQ in spinal nociceptive mechanisms under normal and pathological conditions. Peptides (2000) 21(7):1031-1036.
71. PAN ZZ, HIRAKAWA N, FIELDS HL: A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron (2000) 26(2):515-522.
72. JENCK F, WICHMANN J, DAUTZENBERG FM et al.: A synthetic agonist at the orphanin FQ/nociceptin receptor ORL-1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. USA (2000) 97(9):4938-4943.
73. MOGIL JS, GRISEL JE, ZHANGS G et al.: Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett. (1996) 214(2-3):131-134.
74. GRISEL JE, MOGIL JS, BELKNAP JK et al.: Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. Neuroreport (1996) 7(13):2125-2129.
75. TIAN J-H, XU W, ZHANG W et al.: Involvement of endogenous orphanin FQ in electroacupuncture-induced analgesia. Neuroreport (1997) 8(2):497-500.
76. UEDA H, YAMAGUCHI T, TOKUYAMA S et al.: partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene. Neurosci. Lett. (1997) 237(2,3):136-138.
77. KOTLINSKA J, SUDER P, LEGOWSKA A et al.: Orphanin FQ/nociceptin inhibits morphine withdrawal. Life Sci. (2000) 66(8):PL119-123.
78. WALKER JR, SPINA M, TERENIUS L et al.: Nociceptin fails to affect heroin self-administration in the rat. Neuroreport (1998) 9(10):2243-2247.
79. DEVINE DP, REINSCHEID RK, MONSMA FJ JR et al.: The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. (1996) 727(1,2):225-229.
80. JENCK F, MOREAU J-L, MARTIN JR et al.: Orphanin FQ acts as an anxiolytic to attentuate behavioral responses to stress. Proc. Natl. Acad. Sci. USA (1997) 94(26):14854-14858.
81. GRIEBEL G, PERRAULT G, SANGER DJ: Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res. (1999) 836(1-2):221-224.
82. KOSTER A, MONTKOWSKI A, SCHULZ S et al.: Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. USA (1999) 96(18):10444-10449.
83. OLSZEWSKI PK, LEVINE AS: Minireview: characterization of influence of central nociceptin/orphanin FQ on consummatory behavior. Endocrinology (2004) 145(6):2627-2632.
84. POMONIS JD, BILLINGTON CJ, LEVINE AS: Orphanin FQ, agonist of orphan opioid receptor ORL-1, stimulates feeding in rats. Neuroreport (1996) 8(1):369-371.
85. LEVENTHAL L, MATHIS JP, ROSSI GC et al.: Orphan opioid receptor antisense probes block orphanin FQ-induced hyperphagia. Eur. J. Pharmacol. (1998) 349(1):R1-R3.
86. CICCOCIOPPO R, MARTIN-FARDON R, WEISS F, MASSI M: Nociceptin/orphanin FQ inhibits stress- and CRF-induced anorexia in rats. Neuroreport (2001) 12(6):1145-1149.
87. DAUTZENBERG FM, WICHMANN J, HIGELIN J et al.: Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J. Pharmacol. Exp. Ther. (2001) 298(2):812-819.
88. KAPUSTA, DR, SEZEN SF, CHANG J-K et al.: Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci. (1997) 60(1):PL15-PL21.
89. CHAMPION HC, CZAPLA MA, KADOWITZ PJ: Nociceptin, an endogenous ligand for the ORL-1 receptor, decreases cardiac output and total peripheral resistance in the rat. Peptides (1997) 18(5):729-732.
90. NOSSAMAN, BD, CHAMPION HC, KAYE AD et al.: Nociceptin has vasodilator activity in the pulmonary vascular bed of the rat. J. Cardiovas. Pharmacol. Ther. (1998) 3(3):253-258.
91. WEI Y, HUANG Q, ZHU Y et al.: Potent hypotensive effects of orphanin FQ in conscious stroke-prone spontaneously hypertensive rats. Chin. Med. Sci. J. (1998) 13(2):67-70.
92. 2-NH)Gly2]nociceptin(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J. Pharmacol. Exp. Ther. (1999) 289(1):173-180.
93. GIULIANI S, LECCI A, TRAMONTANA M et al.: The inhibitory effect of nociceptin on the micturition reflex in anesthetized rats. Brit. J. Pharmacol. (1998) 124(7):1566-1572.
94. LECCI A, GIULIANI S, MEINI S et al.: Nociceptin and the micturition reflex. Peptides (2000) 21(7):1007-1021.
95. OSINSKI MA, BROWN DR et al.: Orphanin FQ/nociceptin: a novel neuromodulator of gastrointestinal function? Peptides (2000) 21(7):999-1005.
96. TANIGUCHI H, YOMOTA E, NOGI K et al.: The effect of nociceptin, an endogenous ligand for the ORL-1 receptor, on rat colonic contraction and transit. Eur. J. Pharmacol. (1998) 353(2-3):265-271.
97. CICCOCIOPPO R, ECONOMIDOU D, FEDELI A et al.: The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol. Behav. (2003) 79(1):121-128.
98. CICCOCIOPPOR, PANOCKA I, POLIDORI C et al.: Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacol. (1999) 141(2):220-224.
99. MCLEOD RL, PARRA LE, MUTTER JC et al.: Nociceptin inhibits cough in the guinea-pig by activation of ORL(1) receptors. Brit. J. Pharmacol. (2001) 132(6):1175-8.
100. CORBOZ MR, FERNANDEZ X, EGAN RW et al.: Inhibitory activity of nociceptin/orphanin FQ on capsaicin-induced bronchoconstriction in the guinea-pig. Life Sci. (2001) 69(10):1203-1211.
101. RIZZI A, CALO G, TREVISANI M et al.: Nociceptin receptor activation inhibits tachykinergic nonadrenergic-noncholinergic contraction of guinea pig isolated bronchus. Life Sci. (1999) 64(13):PL157-PL163.
102. CORBOZ MR, RIVELLI MA, EGAN RW et al.: Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung. Eur. J. Pharmacol. (2000) 402(1/2):171-179.
103. ROUGET C, CUI YY, D'AGOSTINO B et al.: Nociceptin inhibits airway microvascular leakage induced by HCl intra-oesophageal instillation. Brit. J. Pharmacol. (2004) 141(6):1077-1083.
104. JIA Y, WANG X, APONTE SI et al.: Nociceptin/orphanin FQ inhibits capsaicin-induced guinea-pig airway contraction through an inward-rectifier potassium channel. Brit. J. Pharmacol. (2002) 135(3):764-770.
105. MANABE T, NODA Y, MAMIYA T et al.: Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature (1998) 394(6693):577-581.
106. MAMIYA T, NODA Y, NISHI M et al.: Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout Mice. Brain Res. (1998) 783(2):236-240.
107. SANDIN J, GEORGIEVA J, SCHOTT PA et al.: Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur. J. Neurosci. (1997) 9(1):194-197.
108. YU T-P, FEIN J, PHAN T et al.: Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus (1997) 7(1):88-94.
109. YU T-P, XIE C-W: Orphanin FQ/nociceptin inhibits synaptic transmission and long-term potentiation in rat dentate gyrus through postsynaptic mechanisms. J. Neurophysiol. (1998) 80(3):1277-1284.
110. HIRAMATSU M, INOUE K: Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory. Eur. J. Pharmacol. (2000) 395(2):149-156.
111. MARTI M, MELA F, VERONESI C et al.: Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. (2004) 24(30):6659-6666.
112. MARTI M, MELA F, GUERRINI R et al.: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. (2004) 91(6):1501-1504.
113. LAZZERI M, CALO G, SPINELLI M et al.: Urodynamic effects of intravesical nociceptin/orphanin FQ in patients with overactive bladder - a randomised, placebo-controlled, double-blind study. European Urology Supplements (2003) 2(1):72.
114. KAPUSTA DR, DAYAN, LA, KENIGS VA et al.: Nociceptin/orphanin FQ modulates the cardiovascular, but not renal, responses to stress in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. (2002) 29(3):254-259.
115. LECUDENNEC C, NAUDIN B, DOREGO J-C et al.: Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection. Life Sci. (2002) 72(2):163-171.
116. JONASSEN TE, HADRUP N, BROEND L et al.: The aquaretic effect of the nociceptin analogue ZP120C is associated with marked downregulation of aquaporin 2. Oral presentation at American Heart Association Scientific Sessions 2002, Chicago, USA, November 17-20, 2002. Circulation (2002) 106(19)(Suppl.II):pII-135; abstract 680.
117. HADRUP N, PETERSEN JS, PRAETORIUS J et al.: Opioid receptor-like-1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation. Am. J. Physiol. (2004) 287(1, Pt.2): F160-F168.
118. KAPUSTA DR, KENIGS VA, VINGE MM, et al.: ZP120C, is a peripherally acting nociceptin analogue with water diuretic and potassium sparing properties. FASEB J. (2002) 16(5, Pt. 2): A841. Poster no. 640.23.
119. RIZZI A, RIZZI D, MARZOLA G et al.: Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand ZP-120: in vitro and in vivo studies in mice. Br. J. Pharmacol. (2002) 137(3):369-374.
120. 35S binding studies. Naunyn-Schmied. Arch. Pharmacol. (2003) 367(2):183-187.
121. GAVIOLI EC, VAUGHAN CW, MARZOLA G et al.: Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice. Naunyn Schmied. Arch. Pharmacol. (2004) 369(6):547-553.
122. HUANG P, KEHNER GB, COWAN A et al.: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. (2001) 297(2):688-695.
123. WNENDT S, KRUGER T, JANOCHA E et al.: Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol. Pharmacol. (1999) 56(2):334-338.
124. LUTFY K, COWAN A: Buprenorphine: a unique drug with complex pharmacology Curr. Neuropharm. (2004) 2(4):395-402.
125. MONTOYA ID, GORELICK DA, PRESTON KL et al.: Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther. (2004) 75(1):34-48.
126. SEKI T, AWAMURA S, KIMURA C et al.: Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur. J. Pharmacol. (1999) 376(1-2):159-167.
127. MIZOGUCHI H, HUNG K-C, LEITERMANN R et al.: Blockade of μ-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. Eur. J. Pharmacol. (2003) 461(1):35-39.
128. PICK CG, PETER Y, SCHREIBER S et al.: Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with κ3 analgesia. Brain Res. (1997) 744(1):41-46.
129. GISTRAK MA, PAUL D, HAHN EF et al.: Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther. (1989) 251(2):469-76.
130. IDDB3 reference: HOHLWEG R, PETTERSSON I: Trans-3-(phenoxymethyl)-4-phenylpiperidines - new selective nociceptin antagonists found by HTS. Int. Symp. Pharm. Chem. 2001 3rd:149-150.
131. RONZONI S, PERETTO I, GIARDINA GAM.: Lead generation and lead optimization approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists. Exp. Opin. Ther. Patents (2001) 11(4):525-546.
132. ZAVERI N: Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL-1: research tools and potential therapeutic agents. Life Sci. (2003) 73(6):663-678.
133. BARLOCCO D, TOMA L, CIGNARELLA G: Non peptidic ligands at the opioid receptor like-1 (ORL-1). Mini Rev. Med. Chem. (2001) 1:363-375.
134. Drug Data Report (2001) 23(3):317.
135. THOMSEN C, HOHLWEG R: 8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist. Br. J. Pharmacol. (2000) 131(5):903-908.
136. KAWAMOTO H, OZAKI S, ITOH Y et al.: Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist. 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl- 4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J. Med. Chem. (1999) 42(25):5061-5063.
137. OZAKI S, KAWAMOTO H, ITOH Y et al.: In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL-1 receptor antagonist. Eur. J. Pharmacol. (2000) 402(1/2):45-53.
138. Drug Data Report (2002) 24(5):403.
139. MARTI M, STOCCHI S, PAGANINI F et al.: Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br. J. Pharmacol. (2003) 138(1):91-98.
140. YAMADA H, NAKAMOTO H, SUZUKI Y et al.: Pharmacological profiles of a novel opioid receptor-like-1 (ORL-1) receptor antagonist, JTC-801. Br. J. Pharmacol. (2002) 135(2):323-332.
141. MURATINI T, MINAMI T, ENOMOTO U et al.: Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2- (4-ethylphenoxymethyl)benzamide monohydrochloride. J. Pharmacol. Exp. Ther. (2002) 303(1):424-430.
142. SHINKAI H, ITO T, IIDA T et al.: 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. J. Med. Chem. (2000) 43(24):4667-4677.
143. Drug Data Report (2003) 25(11):1001.